Stock Taper
ENTX
ENTERA BIO LTD.
NASDAQ
$3.03
▼ DOWN 1.62% (-0.05)

KEY STATISTICS

Market Cap$149.35 M
52w High$4.20
52w Low$0.91
Dividend Yield
Frequency
P/E-8.66
Volume138.02K
Shares Out.49.29M

COMPANY

LEADERSHIP

Miranda J. Toledano
CHIEF EXECUTIVE
Miranda J. Toledano

COMPENSATION 2026

Salary$419
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,149

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 28, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
21

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.
NOV
13
FRI

PRICE

$3.03 ▼ DOWN 1.62% (−$0.05)
$3.00$3.05$3.10$3.159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.03

About Entera Bio Ltd.

https://www.enterabio.com ↗

Entera Bio Ltd. is a Jerusalem-based clinical-stage biopharmaceutical company developing oral large molecule therapeutics, with lead candidates in Phase II for hypoparathyroidism and osteoporosis, and collaborations with Amgen.

INDUSTRY

Biotechnology

A PRODUCT ENTERA BIO LTD. IS KNOWN FOR

EB613
EB613

Entera Bio is developing the first once-daily oral teriparatide tablet for post-menopausal osteoporosis, with its lead candidate preparing for Phase 3 trials and representing the company's main commercial focus.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

OFFICER
Camisasca Riccardo Paolo
· —
2026-08-18
OFFICER: CHIEF OF R&D
Burshtein Gregory
Purchase · 180.0K shares
2026-08-07
DIRECTOR
Ellis Sean
Purchase · 20.0K shares
2026-08-07
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Toledano Miranda Jayne
Purchase · 200.0K shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
AGEN$7.66COMPARE
IRD$3.69COMPARE
ABOS$2.92COMPARE
HURA$2.11COMPARE
ANIX$3.48COMPARE
SEER$1.98COMPARE
INO$1.29COMPARE
SPRO$1.20COMPARE